• Parasites, Hosts and Diseases
• /
• 제31권4호
• /
• pp.353-362
• /
• 1993

Fibricola seoulensis의 성체와 피낭유충에서 acid(Acpase)와 alkaline phosphatase (AIPase)의 분포와 동위효소유형 (유형)의 변화를 추구하고자 효소조직화학적 방법과 전기영동법을 이용하여 성체에서 Acpase는 pH 5가 최적의 활성이 나타났고. 분자량이 95 kDa. 85 kDa. 73 kDa. 62 kDa인 4종류의 동위효소가 동정되었다. 피낭유충에서 A쳬ase는 활성이 약하거나 나타나지 않았고. 분자량이 62 kDa인 1종류의 동위효소가 동정되었다 성체와 피낭유충에 AIPase는 pH 8에서 최적의 활성이 나타났고, 피낭유충의 생식원기에서 강한 활성이 나타났다.

• 미생물학회지
• /
• 제23권3호
• /
• pp.172-176
• /
• 1985

본 연구는 효모세포 (Saccharomyces uvarum)의 ACPase, ALPase의 Isoenzyme type을 규명함과 아울러, iso-enzyme type중 어느 것이 constituitive 또는 repressible enzyme type인가를 조사하고, 각각의 isoenzyme활성도 비율을 살펴보아 배양조건(catabolic repression and derepression) 및 무기인산 제한에 따른 각 type의 세포내 조절기능을 분석하고자 하였다. Acid phosphatase는 또 다른 isoenzyme type이 발견되지 않았으나, alkaline phosphatase의 경우는 3가지 type이 p-NPP에 specificity를 지녔다. 세포질의 수용성단백질 분석결과 exponential phase의 세포는 주로 음전하를 띤 단백질이 높은 함량을 나타내었다. 당과 인산이 결핍된 배지에서 생육권(catabolic repression)세포에서 AL P Pase isoenzyme 중 type “B"의 활성도가 매우 높아졌으나, 완전배지에서 배양된 (catabolic derepression)세포에서는 type “B"의 활성도 감소 및 type “C"의 활성도 증가 현상을 볼 수 있었다. ALPase 중 “A" peak는 constituitive enzyme, “B" peak는 repressible enzyme, peak “C"는 L-histidinol phosphatase로 추정되었다.

• BMB Reports
• /
• 제34권6호
• /
• pp.517-525
• /
• 2001

Six renaturable protein kinases that utilize the myelin basic protein (MBP) as a substrate were activated during prolonged exposure of cardiac myocytes to okadaic acid (OA). We characterized the substrate preference and activation of these kinases, with particular emphasis on 3 novel kinases-MBPK-55, MBPK-62 and MBPK-87. The transcription factors c-Jun, Elk, ATF2, and c-Fos that are used to assess mitogen-activated protein kinase activation were all poor substrates for these three kinases. MAPKAPK2 was also not phosphorylated. In contrast, Histone IIIS was phosphorylated by MBPK-55 and MBPK-62. These protein kinases were activated in cultured cardiac fibroblasts, H9c2 cardiac myoblasts, and Cos cells. High concentrations (0.5 to $1\;{\mu}M$) of OA were essential for the activation of the protein kinases in all of the cell types examined, whereas calyculin A [an inhibitor of protein phosphatase 1 (PP1) and PP2A], cyclosporin A (a PP2B inhibitor), and an inactive OA analog all failed to activate these kinases. The high dose of okadaic acid that is required for kinase activation was also required for phosphatase inhibition, as assessed by immunoblotting whole cell lysates with anti-phosphothreonine antibodies. A variety of chemical inhibitors, including PD98059 (MEK-specific), genistein (tyrosine kinase-specific) and Bisindolylmaleimide I (protein kinase C-specific), failed to inhibit the OA activation of these kinases. Thus, MBPK-55 and MBPK-62 are also Histone IIIS kinases that are widely expressed and specifically activated upon exposure to high OA concentrations.

• Bulletin of the Korean Chemical Society
• /
• 제34권4호
• /
• pp.1275-1277
• /
• 2013

• 한국응용곤충학회:학술대회논문집
• /
• 한국응용곤충학회 2005년도 춘계 학술발표회
• /
• pp.109-109
• /
• 2005

• Bulletin of the Korean Chemical Society
• /
• 제32권1호
• /
• pp.31-32
• /
• 2011

• Bulletin of the Korean Chemical Society
• /
• 제25권9호
• /
• pp.1303-1304
• /
• 2004

• BMB Reports
• /
• 제50권6호
• /
• pp.329-334
• /
• 2017

Protein tyrosine phosphatases (PTPs) play crucial roles in signal transduction and their functional alteration has been detected in many diseases. PTP inhibitors have been developed as therapeutic drugs for diseases that are related to the activity of PTPs. In this study, PTP inhibitor XIX, an inhibitor of CD45 and PTEN, was investigated whether it inhibits other PTPs. Protein tyrosine phosphatase non-receptor type 2 (PTPN2) was selectively inhibited by the inhibitor in a competitive manner. Drug affinity responsive target stability (DARTS) analysis showed that the inhibitor induces conformational changes in PTPN2. Phosphorylation levels of signal transducer and activator of transcription 3 (STAT3) at Tyr-705, a crucial site for STAT3 activation and target site of PTPN2, decreased upon exposure to the inhibitor. Our results suggest that PTP inhibitor XIX might be considered as an effective regulator of PTPN2 for treating diseases related to PTPN2.

• BMB Reports
• /
• 제41권12호
• /
• pp.881-885
• /
• 2008

Protein phosphatase 1 consists of a secondary structure arrangement, conserved in the serine/threonine protein phosphatase gene family, flanked by nonconserved N-terminal and C-terminal domains. The deletion mutant of PP1 with the 8 nonconserved N-terminal residues removed was designated PP1-(9-330). PP1-(9-330) had a higher activity and affinity than PP1 when assayed against four different substrates, and it also demonstrated a 6-fold higher sensitivity to the inhibitor okadaic acid. This suggested that the N-terminal domain suppresed the activity of PP1 and interfered with its inhibition by okadaic acid. The ANS fluorescence intensity of PP1-(9-330) was greater than that of PP1, which implies that the hydrophobic groove running from active site in the truncated PP1 was more hydrophobic than in PP1. Our findings provide evidence that the nonconserved N-terminus of PP1 functions as an important regulatory domain that influences the active site and its pertinent properties.

• BMB Reports
• /
• 제56권11호
• /
• pp.618-623
• /
• 2023

Most cancer cells utilize glucose at a high rate to produce energy and precursors for the biosynthesis of macromolecules such as lipids, proteins, and nucleic acids. This phenomenon is called the Warburg effect or aerobic glycolysis- this distinct characteristic is an attractive target for developing anticancer drugs. Here, we found that Phosphofructokinase-1 (PFK-1) is a substrate of the Protein Phosphatase 4 catalytic subunit (PP4C)/PP4 regulatory subunit 1 (PP4R1) complex by using immunoprecipitation and in vitro assay. While manipulation of PP4C/PP4R1 does not have a critical impact on PFK-1 expression, the absence of the PP4C/PP4R1 complex increases PFK-1 activity. Although PP4C depletion or overexpression does not cause a dramatic change in the overall glycolytic rate, PP4R1 depletion induces a considerable increase in both basal and compensatory glycolytic rates, as well as the oxygen consumption rate, indicating oxidative phosphorylation. Collectively, the PP4C/PP4R1 complex regulates PFK-1 activity by reversing its phosphorylation and is a promising candidate for treating glycolytic disorders and cancers. Targeting PP4R1 could be a more efficient and safer strategy to avoid pleiotropic effects than targeting PP4C directly.